In the triple-therapy group, the most common grades 3–4 adverse events were neutropenia (30.4%), abdominal pain (28.4%), thrombocytopenia (25.3%), and increased alanine aminotransferase and aspartate aminotransferase (22.2 and 23.2% for each), which were consistent with those that occurred in a previous study10. This evidence concerns the gene GPT and neutropenia.